leadXpro and Alipheron are combining their cutting-edge technologies to bring a new level of innovation to early drug discovery.
By applying intelligent algorithms to detect new drugs in trillions of molecules By using high-tech Cryo-EM to elucidate structures of membrane bound proteins By accelerating structure-based lead discovery to address unmet medical needs
Cumulus Oncology and leadXpro Achieve Critical Milestone in GPR68 Drug Discovery Project
Edinburgh, Scotland, and Villigen, Switzerland, 13 August 2024 – Cumulus Oncology, Europe’s first oncology-focused biotech creation company, announces that, in partnership with its collaborator leadXpro (LXP), key milestones have been achieved in their protein structure driven GPR68 drug discovery project. As a result, Cumulus has licensed the small molecule compounds and associated IP created during […]
Golgi Neurosciences and leadXpro announce collaboration on GPR65 modulators
Milan, Italy, and Villigen, Switzerland 29th May 2024. Today, we are happy to announce our partnership with Golgi Neurosciences, a pioneering company-creator boutique dedicated to developing therapies for neurodegenerative diseases.Together, we created significant progress with different classes of positive and negative modulators of GPR65, a proton-sensing G protein–coupled receptor (GPCR). This receptor is involved in […]
2nd Ace Drug Discovery Summit
We are delighted to share the exciting news that Juana Lucia Flores-Candia, esteemed Board Member at leadXpro AG, is set to grace the stage at our forthcoming 2nd Ace Drug Discovery Summit (ADDS) at The Insurance Hall in London on the 20th and 21st of March 2024.Don’t miss the opportunity to be part of the […]
Cumulus Oncology and leadXpro Announce Collaboration to Develop Small Molecules against Novel Cancer-Focused GPCR Targets
Cumulus Oncology and leadXpro Announce Collaboration.
Resulting IP will be licensed into a newly created Cumulus company
SCIENTIFIC WEBINAR
Early drug discovery requires an interdisciplinary approach with a sophisticated interplay between empirical methods and rational design. Amongst the different therapeutic modalities, orally available small molecules are a major pillar for safe treatment of acute and chronic diseases.
RaQualia Pharma and leadXpro Announce Collaboration to Accelerate Drug Discovery on Intractable Membrane Protein Targets
In this collaboration, leadXpro will establish robust protocols and workflows to facilitate the rapid determination
Septerna Engages leadXpro to Discover Novel Binding Partners to GPCR Targets for use in Internal Drug Discovery Programs
During this engagement, leadXpro will use membrane proteins selected by Septerna to discover novel binding partners to…
First CrySol VitroJet in Switzerland
We are thrilled to announce that leadXpro has extended its cryo-EM facility with the latest technology in sample preparation solution, the VitroJet. This cutting-edge technology is the first of its kind in Switzerland.
leadXpro has just elucidated the world’s first structure of a proton-sensing GPCR target
To date, no structural information has been reported for the entire H+ activated GPCR family.
Colocalized targeting of TGF-beta and PD-L1 by bintrafusp alfa elicits distinct antitumor responses
In collaboration with Merck/Serono, leadXpro confirmed the colocalization aspect of the mode of action of bintrafusp alfa using Cryo-Electron Microscopy
Five Opportunities at the Interface Between Structural Biology and AI and their Impact on Drug Discovery
by Denis Bucher, Principal Scientist at leadXpro and Head of Molecular Modelling and Design
leadXpro joins the MabDesign Network
leadXpro AG is a sponsor of the MabDesign Network, which aims at structuration of the immunotherapeutics research sector.
CEO Michael Hennig presents at Drug Discovery Chemistry 2022
Listen to Michael Hennig’s talk at DDC 2022 about the impact of CGI and other biophysical methods on drug discovery for membrane proteins
Attend leadXpro’s lecture on Cryo-EM at PSDI 2021
The PSDI conference 2021 will take place online. leadXpro scientist Mathieu Botte will present on Cryo-EM applications.
M&M 2021 virtual meeting
At the M&M meeting, leadXpro CEO Michael Hennig will present «Advances in Cryo-EM structure-based methods in membrane protein drug discovery», highlighting recent work on TRPV4, LPTDE and a potassium channel.
First structure of human Kv3.1 channel
In collaboration with Lundbeck, leadXpro solved the first structure of a human Kv3 channel in complex with a positive modulator.
CryoEM Structure of Lipopolysaccharide Transporter LptDE Opens the Door to Antibiotics Design
Together with the Basel Biozentrum and the Institute of Medical Microbiology in Zurich, leadXpro solved the structure of the bacterial transporter LptDE to provide structural basis for the design of novel antibiotics.
Meet leadXpro CEO Michael Hennig at the Symeres Webinar
leadXpro CEO Michael Hennig showcases examples of successful structure based drug discovery for challenging membrane targets
First Cryo-EM structure of the human TRPV4 ion-channel in the open conformation, in complex with an agonist.
In partnership with Bayer, leadXpro has generated protein and solved the cryo-EM structure of human TRPV4 in complex with the agonist 4α-PDD, providing novel information about agonist binding to this important drug target.
Join us at the Creoptix waveRAPID launch event
leadXpro supports Creoptix at the launch event for the new waveRAPID kinetics analyzer
leadXpro celebrates its 5th anniversary
On December 2, 2020, leadXpro proudly celebrates its fifth anniversary and looks back on many successful projects with challenging membrane targets.
Strategic Alliance with Axxam and MercachemSyncom
Axxam, leadXpro and MercachemSyncom Form a Strategic Alliance for Structure-based Drug Discovery Services that will allow them to offer world-class integrated structure-guided drug discovery services for membrane protein targets.
Enabling design of selective antagonists for the CC Chemokine receptor 2A (CCR2A)
In a partnership with Boehringer Ingelheim, leadXpro generated protein and provided the X-ray structure data to advance their drug discovery programs on CCR2, a chemokine receptor target.
Transforming drug discovery on membrane proteins
Creoptix CEO Line S. Raquet and leadXpro CEO Michael Hennig look back on three years of partnership that transformed membrane protein drug discovery.
Advances in long-wavelength native phasing at X-ray free-electron lasers
leadXpro, PSI, ETH and Sosei Heptares scientists present sensitivity improvements for XFEL measurements by using long wavelength pulses and improvements in data evaluation.
Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell function including CD103+ dendritic cells enhancing anti-tumor immunity
The publication provides evidence implicating suppression of adaptive and innate immunity by adenosine as a mechanism for immune evasion by tumors. Inhibition of adenosine signaling through selective small molecule inhibition of A R using AZD4635 restores T cell function
cross-presentation by CD103+ DCs resulting in antitumor immunity.
leadXpro produces protein for COVID-19 research campaign
leadXpro AG announces its involvement in a multiparty research collaboration by delivering SARS-CoV-2 M-glycoprotein, a promising therapeutic target against Covid-19.
Towards an Optimal Sample Delivery Method for Serial Crystallography at XFEL
This crystallography review summarizes the current main strategies in sample delivery and their respective pros and cons, as well as some future direction.
leadXpro, first tenant of Park InnovAARE’s innovation campus
One month after the groundbreaking ceremony of Park Innovaare’s new Innovation Campus, leadXpro is the first company to sign a tenancy agreement.
In situ crystallography as an emerging method for structure solution of membrane proteins: the case of CCR2A
The in meso in situ serial X-ray crystallization method enables structure determination of very fragile crystals.
Biophysical Assessment of Target Protein Quality in Structure‐Based Drug Discovery
leadXpro CEO Michael Hennig contributes a chapter about the progress of structure biology in drug discovery
leadXpro and Lundbeck partner for membrane protein structure research
Lundbeck partners with leadXpro to discover drugs for membrane protein targets by high-resolution X-ray and cryo-Electron Microscopy
leadXpro and Astex enter partnership on membrane protein structure research
Astex Pharmaceuticals partners with leadXpro to facilitate structure-based drug discovery for membrane protein targets by cryo-Electron Microscopy
leadXpro licenses cryoSPARC™ software
By licensing cryosparc software and upgrading of its in-house computing capacity, leadXpro enhances its ability for high resolution structure determination of membrane protein drug targets by single particle cryo-Electron Microscopy (cryo-EM)
Crystal Structure of CC Chemokine Receptor 2A in Complex with an Orthosteric Antagonist Provides Insights for the Design of Selective Antagonists
Two independent structures of CCR2A in complex with the orthosteric antagonist MK-0812 were solved, confirming the importance of residue E2917.39 for antagonist binding. Structural modeling of pyrimidine amide antagonists showed an interaction with the non-conserved H1213.33, leading to a significant selectivity over CCR5, suggesting strategies for highly selective CCR2 antagonist design.
Symposium on Drug Discovery @ SwissFEL
The registration for the International Symposium on Structure Biology for Drug Discovery@SwissFEL on June 25-27, 2019 in Villigen, Switzerland is now open.
Collaboration with Sanofi on cryo-EM based structure research
leadXpro and Sanofi collaborate for cryo-EM structure project
First biomolecular structure experiment at SwissFEL
leadXpro determined the first protein structure at the Swiss Free Electron Laser (SwissFEL) facilities.
Collaboration with the University of Zürich on membrane protein targeted sybodies
leadXpro AG and the University of Zurich (UZH) collaborate to generate sybodies as molecular discovery tools, therapeutic lead compounds and diagnostic reagents against disease-relevant membrane protein targets.
Collaboration with InterAx on new immune oncology drugs
leadXpro AG and InterAx Biotech AG, join forces to discover and optimize new drug lead molecules targeting G-protein coupled receptors.
Towards high throughput GPCR crystallography: In Meso soaking of Adenosine A2A Receptor crystals
The paper reports an efficient method to generate multiple co-structures of the A2A G protein-coupled receptor (GPCR) with small-molecules from a single preparation of a thermostabilised receptor crystallised in Lipidic Cubic Phase (LCP)
CTI grants leadXpro startup label
The Swiss Commission for Technology and Innovation CTI awards leadXpro the CTI startup label.
BASF and leadXpro announce research collaboration
BASF and leadXpro AG will join forces to collaborate on the structure-based discovery of new active ingredients by employing single particle cryo-electron microscopy.
leadXpro scientists chart the future of structure based drug discovery
leadXpro AG scientists explore the utility of cutting-edge X-ray technologies for the discovery of new therapeutics.
leadXpro adopts creoptix’ wave technology for ligand characterization
Creoptix and leadXpro AG announce the selection of the Creoptix WAVE technology by leadXpro to strengthen its capabilities for drug discovery aimed at identifying and optimizing drug candidates directed against challenging membrane protein drug targets.
X-ray Free Electron Laser: Opportunities for drug discovery
The authors demonstrate that XFEL structure determination has matured to reality and point out the many advantages of the technology: Unmet brilliance and focus, femtosecond pulses and low/no radiation damage and measurement at room temperature allow structure determinations of challenging systems like membrane proteins, investigation of time-resolved ligand binding, new structural insights due to room temperature and full automation of crystal diffraction experiments.
leadXpro and AXXAM collaborate on novel inflammatory GPCR target
leadXpro and AXXAM announce the collaboration for the discovery of small molecular ligands to a novel inflammation related GPCR target.
Serial millisecond crystallography for routine room-temperature structure determination at synchrotrons
We demonstrate that serial millisecond crystallography at a synchrotron beamline equipped with high-viscosity injector and high frame-rate detector allows typical crystallographic experiments to be performed at room-temperature.
Structural biology: doors open at the European XFEL
A technology feature by Nature Methods’ technology editor Vivien Marx about free electron lasers to comment on the opening of the European X-ray Free Electron Laser (EuXFEL) in Hamburg, Germany.
New Operational Space and Funding ensures further growth of LEADXPRO
Tripling its physical footprint and with a new funding round secured, leadXpro AG is well-prepared for further development.
GPCR-ligand complex structure within 4 months
In collaboration with a major pharma company, leadXpro AG announced today the successful delivery of multiple GPCR structure determination milestones ahead of schedule.
leadXpro enters collaboration on cryo-EM based new lead discovery with Bayer
leadXpro AG announced today a collaboration with Bayer AG to enable structure based drug discovery of membrane protein targets, facilitated by single particle cryo-Electron Microscopy (cryo-EM)
PARK INNOVAARE files building application for leadXpro’s future home
Park InnovAARE files building application for leadXpro’s future home
leadXpro and Boehringer Ingelheim collaborate on membrane protein drug target
leadXpro proudly reports a collaboration contract with Boehringer Ingelheim
leadXpro celebrates its first anniversary
LeadXpro takes its place as world leading structure based drug discovery company and celebrates its first anniversary
leadXpro and Paul Scherrer Institute sign agreement on Beam Line at the Swiss Light Source
Agreement with Paul Scherrer Institute on a beam line at the Swiss Light Source SLS
leadXpro at the PSDI conference
Michael Hennig (CEO, leadXpro) will chair and open the session on „Membrane proteins & hot structures“ at the PSDI 2016 conference with a talk on „Extension of structure based drug discovery on membrane proteins, update on recent developments and examples“.
Further development of Serial Crystallography
leadXpro and PSI scientists team up to develop further serial crystallography
Biophysics in drug discovery: impact, challenges and opportunities
A review by CEO Michael Hennig that discusses challenges and opportunities for biophysical methods in drug discovery.
Heptares and leadXpro enter collaboration on GPCR biostructure
Heptares and leadXpro enter collaboration on powerful new approaches to GPCR structure determination for drug discovery
